Semax: Unapproved Outside Russia, and Thinner on Human Evidence Than It Looks

Reviewed by the NootropicsJet editorial team · Published: [6-8-2026] · Last updated: [24-08-2026]

Based on the FDA’s 2026 evaluation of semax-related bulk drug substances prepared for the Pharmacy Compounding Advisory Committee, the human studies that evaluation identified, and the preclinical literature it cites.

Semax is a synthetic peptide that is a prescription medicine in Russia and an unapproved research chemical almost everywhere else. Online it is sold as a focus and mood compound.

In July 2026 an FDA advisory committee voted to recommend it for a compounding list — overruling the agency’s own scientists, who had assembled the evidence and concluded it was insufficient. This article walks through what that record actually contains, what the vote did and did not change, which risks the agency flagged that nootropics coverage almost never mentions, and how to think about the gap between a peptide’s mechanism and a person’s Tuesday afternoon.

Key takeaways

The entire published human record FDA could evaluate covers roughly 33–47 healthy adults, 69 adults with medical conditions, and 451 children — and not one pharmacokinetic study in humans by any route. Every “half-life” figure circulating online comes from rats.
No published, English-language controlled trial has tested whether semax improves cognition in healthy adults. The one placebo-controlled healthy-adult study measured brain imaging, not thinking.
On July 23–24, 2026, FDA’s advisory committee voted to recommend semax for the Section 503A compounding list — against FDA staff’s written recommendation. Compounding it is still not lawful, and semax is still not an approved drug in the US or EU.
Both nominations for semax had been withdrawn by the nominators. FDA elected to evaluate the substance at its own discretion anyway.
FDA’s search of its adverse event database returned exactly one report: a consumer hospitalized after using semax nasal drops bought online, whose eye pain had not resolved a year later.
FDA flagged two interaction signals that nootropics coverage routinely omits: anticoagulant and antiplatelet activity in rodents, and potentiation of amphetamine-induced dopamine release in mice.

What semax is, and why the “ACTH analogue” label misleads people

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro, developed in the 1980s at the Institute of Molecular Genetics of the Russian Academy of Sciences, in a program that searched for stable analogues of adrenocorticotropic hormone (ACTH) fragments.

Most articles describe semax as an “ACTH(4–10) analogue.” That is the conventional shorthand, and it is half right. The parent fragment ACTH(4–10) is Met-Glu-His-Phe-Arg-Trp-Gly. Semax keeps the first four residues and replaces Arg-Trp-Gly with Pro-Gly-Pro. The tail was not appended to an intact fragment; it substituted for three amino acids.

That substitution does two things at once: it resists cleavage by carboxypeptidases, and it removes the corticotropic and melanotropic activity of the parent hormone.

So the persistent claim that semax raises cortisol because it “comes from ACTH” is wrong — and wrong for a specific structural reason rather than a hand-wave. Semax is consistently characterized in the pharmacology literature as devoid of hormonal corticotropic and melanotropic properties while retaining neurobehavioral activity.

What that means for you: the ACTH lineage tells you where the molecule came from. It does not tell you what it does, and it is not a reason to expect adrenal or stress-hormone effects in either direction.

Is semax legal? Where it stands with the FDA, the EU, and Russia

Semax is a registered prescription drug in the Russian Federation, sold as nasal drops. It has no marketing authorization from the FDA, the EMA, or the MHRA. In the United States and the EU it is neither an approved medicine nor a lawful dietary supplement ingredient — a synthetic peptide drug does not qualify as a food. Products reaching Western buyers are labeled research chemicals.

Approval in one jurisdiction reflects one regulator’s standards and the dossier submitted to it. Russian registration covers cerebrovascular and neurological indications in diagnosed patients. It is not a finding that semax is safe or effective for a healthy adult who wants to concentrate better, and no regulator anywhere has evaluated it for that purpose.

This is the same regulatory posture we describe for Noopept and the actoprotectors: a Soviet-era research tradition, domestic approval, and a literature that has never been independently replicated outside its country of origin.

What it is actually sold for. In surveying how semax reaches US buyers, FDA catalogued the conditions it is marketed online to address: anxiety, depression, attention and memory improvement, ischemic events and stroke, nerve regeneration, diabetic neuropathy, ADHD, opioid withdrawal, amyotrophic lateral sclerosis, Parkinson’s disease, Alzheimer’s disease, dyscirculatory encephalopathy, optic nerve atrophy, pain, and gastric protection.

Fifteen conditions, for a compound with no approved indication outside Russia and a human evidence base of a few hundred people. A product marketed for everything is being marketed on the basis of nothing in particular.

FDA also noted that no outsourcing facility has reported compounding semax since 2019, and that a Kentucky compounding pharmacy and its owner were sentenced for unlawful distribution after compounding and distributing products containing semax between October 2018 and April 2020.

What the July 2026 FDA advisory vote changed — and what it didn’t

On July 23–24, 2026, FDA’s Pharmacy Compounding Advisory Committee reviewed seven peptides — BPC-157, KPV, TB-500, MOTS-c, Emideltide (DSIP), Semax and Epitalon, each in free base and acetate forms — for the Section 503A Bulks List. That list permits licensed pharmacists and physicians to compound with a bulk substance that has no USP monograph and is not a component of an approved drug. Semax fails both alternative criteria, so the list is the only lawful compounding route.

FDA staff proposed that every one of the seven not be included. In the briefing document, the agency’s stated position on the final two votes of the meeting was unambiguous: FDA is proposing that Semax (free base) NOT be included on the 503A Bulks List, and the same for semax acetate.

The committee voted the other way. Across a series of narrow votes it recommended six of the seven — all except emideltide — for inclusion.

A procedural detail worth knowing. Both nominations for semax, from LDT Health Solutions on behalf of the International Peptide Society and from Wells Pharmacy Network, had been withdrawn by the nominators. FDA elected to proceed with the presentation regardless. The same was true of every other peptide on the agenda. The substance the committee ultimately recommended was one nobody was formally still asking for.

Three things follow, and they are frequently confused:

Nothing is legal that wasn’t legal before. PCAC recommendations are advisory. Compounding semax remains impermissible until FDA accepts the recommendation and completes notice-and-comment rulemaking, with the Secretary of Health and Human Services formally approving the addition.
A listing would not be an approval. The 503A list governs what a pharmacist may compound on a prescription. It is not a determination that a substance is safe and effective, and it involves no new drug application review.
The staff objections still stand as written. The vote generated no new data. FDA evaluates a nominated substance against four criteria set out in its 2019 final rule — the physical and chemical characterization of the substance; any safety issues raised by its use in compounded drug products; the available evidence of effectiveness or lack of effectiveness; and historical use in compounding, including the conditions treated and references in peer-reviewed medical literature. The agency applies these as a balancing test, weighing each criterion in the context of the others on a substance-by-substance basis. Its evaluation of semax against that framework remains the most detailed regulatory assessment of the compound in English.

One more thing coverage tends to skip. The committee that produced these votes had been recently reconstituted, and the composition drew conflict-of-interest scrutiny, with increased representation from clinicians and businesses involved in prescribing, producing or promoting peptides. That does not make the votes wrong. It is context a reader deserves when weighing an advisory panel against the career reviewers it overruled.

A second PCAC meeting covering additional peptides is expected in 2027.

What the human evidence on semax actually consists of

Here is the complete set of human studies FDA identified and could assess. Read as an inventory, it is smaller than the compound’s reputation implies.

Russian-language publications were excluded from the agency’s review under a regulation requiring verified English translations — a procedural exclusion, not a judgment on their quality. That distinction is discussed below.

Study	Population	Administered	Result
Kaplan et al., 1996	19 healthy adult men	Intranasal 1 mg/day × 2 days, or 0.25 mg once	Reported nootropic-like activity; adverse events not discussed
Koroleva et al., 1996	37 adults with pain (migraine, trigeminal neuralgia, dental plexalgia)	Single intranasal 0.5 mg/kg	Mixed to null — see below. Authors reported no adverse events
Ivanikov et al., 2002	32 adults with peptic ulcer	1% solution, 2–4 drops per nostril 3×/day × 10 days, added to omeprazole, bismuth and solcoseryl	Semax’s contribution not separable from concomitant therapy
Cherkasova et al., 2002 (abstract)	Unstated number, chronic ischemic brain disease	Intranasal, 10 days	Full results not reported; FDA could not determine whether labs were from the human or animal arm
Lebedeva et al., 2018	14 healthy adults received semax	Intranasal 1.2 mg	Resting-state fMRI difference in default mode network
Panikratova et al., 2020	14 healthy adults received semax	Intranasal 1.2 mg	Functional connectivity differences. FDA notes the sample may overlap with Lebedeva 2018
Proskurina et al., 2018 (abstract)	120 children aged 12–14 with depression	Semax 0.1% plus CBT plus physiotherapy	Contribution of semax not separable
Aminova et al., 2016 (abstract)	331 children with tics/Tourette syndrome	Semax plus pyritinol plus neuroleptics	Contribution of semax not separable

In total: roughly 33–47 healthy adults, 69 adults with medical conditions, and 451 children. Three of the references are professional society meeting abstracts. In one reference the authors reported no adverse events; in the rest, adverse events were not discussed at all.

Doses above describe what was administered in those specific studies. They are not recommendations. No dose of semax has been established for cognitive enhancement in healthy adults, and this article does not provide a protocol.

Read the table as a whole and three things stand out.

The pediatric studies carry no information about healthy adults. They are combination-therapy abstracts in clinical populations, and the contribution of semax is not separable from cognitive behavioural therapy, physiotherapy, pyritinol or neuroleptics.

The pain literature points toward a null result that online summaries routinely invert. In the migraine group — 12 subjects — four reported cessation of headache pain at 90 to 120 minutes, while in the other eight the authors described the effect as weaker, with pain reduced but not eliminated. In the 16 subjects with typical trigeminal neuralgia there were no changes in pain characteristics, sensation or pain thresholds, or evoked potentials. The authors’ own conclusion: semax does not exhibit analgesic activity by itself. FDA’s verdict on the migraine arm was that this one small, uncontrolled, open-label study showed semax was not effective in resolving headache pain for the majority of subjects (Koroleva et al., 1996, Bull Exp Biol Med 122(11):1107–1109, PMID 8998343).

The only placebo-controlled healthy-adult work measures an imaging metric, not performance. More on that below.

What FDA did — and did not — agree to evaluate

The nominators proposed semax for ADHD, cerebral ischemia, analgesia and “nootropic” use. FDA declined to evaluate the ADHD claim at all, on the grounds that supporting literature for that use was not found.

The handling of the word “nootropic” is worth reading closely, because it exposes a definitional gap the whole consumer category sits inside. FDA noted that “nootropic” has no ICD-10 code and no professional society treatment guidelines, and turned to a medical dictionary, which defines it as having positive effects on organically impaired cognition or nervous system function. On that definition, the agency folded the nootropic claim into its analysis of cerebral ischemia.

In other words: the formal medical definition of a nootropic concerns impaired cognition. It does not describe enhancement in a healthy person — which is what the compound is actually sold for.

FDA’s overall conclusion on effectiveness was that only two usable references existed, both with insufficient detail on design and conduct, and that the available references demonstrated lack of effectiveness and were limited by small sample size.

Does semax improve focus or mood in healthy adults?

No published, English-language controlled trial has tested this.

The closest evidence is Lebedeva et al. (2018, Bull Exp Biol Med 165(5):653–656, PMID 30225715): a placebo-controlled resting-state fMRI study in 24 healthy volunteers that found a larger rostral default-mode-network subcomponent in the semax group at 5 and 20 minutes after a single intranasal dose. A companion analysis by the same group examined functional connectivity under semax and selank (Panikratova et al., 2020, Dokl Biol Sci 490(1):9–11, PMID 32342318).

That study earns real credit. It has a placebo arm and pre/post imaging, which puts it above most of the surrounding literature. But the endpoint is network topography. Nobody was asked to remember a word list, sustain attention through a vigilance task, or complete a piece of work. A drug can measurably alter a resting-state network and produce no detectable change in what a person can do — pharmacological fMRI is full of examples.

Evidence tier: Preliminary for “semax measurably alters brain network activity in healthy adults.” No tier for “semax improves focus, mood, or productivity in healthy adults” — that claim has not been tested.

The subjective reports that circulate — smoother task initiation, less late-session fatigue, steadier verbal fluency — are worth taking seriously as a reason to investigate, and worth nothing as evidence. They are inseparable from sleep quality, workload, caffeine, novelty and expectancy, all of which move the same needle in the same direction.

What about the Russian stroke literature?

Semax’s registration in Russia rests substantially on clinical work in acute ischemic stroke, published in Russian. FDA could not consider those papers, because its regulations require verified English translations that nobody supplied.

That is an honest reason to hold the question open rather than close it in either direction. The studies may be sound. They also have not been assessed by any regulator outside Russia, and have not been independently replicated.

What the literature does not support is transfer. Neuroprotection in tissue that is already ischemic and a cognitive benefit in intact, well-rested tissue are different questions, and evidence for one is not evidence for the other. A compound that limits infarct expansion in a damaged brain need not do anything detectable in a healthy one; the two effects often do not correlate at all.

Any framing in which stroke registration in Russia becomes a reason to expect sharper focus at your desk is an extrapolation — and it is the single most common error in coverage of this peptide.

Semax mechanism: what the biology suggests, and what it can’t tell you

Neurotrophic signaling. The most cited mechanism is upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF). In rats given semax intranasally, expression of both increased across brain regions including the hippocampus within an hour. The mechanism by which semax regulates this gene expression is unknown.

Monoamines. In mice, semax dose-dependently raised extracellular striatal 5-HIAA, a serotonin metabolite. Cyproheptadine, a serotonin receptor antagonist, blocked semax-induced analgesia in rats, which led those authors to propose a serotonergic contribution.

Ischemia models. In rats with photothrombotic focal ischemia treated intranasally, infarcted areas were smaller than vehicle at eight days, and treated animals did not show the memory retention deficit that vehicle-treated animals did.

Evidence tier: Mechanistic for all of the above. Every finding is rodent or in vitro. None has been demonstrated in humans.

What that means for you: “increases BDNF expression in rat hippocampus” and “improves human learning” are separated by a great deal of work that nobody has done. BDNF is genuinely central to synaptic plasticity, which is exactly why the mechanism attracts attention — and exactly why it generates confident marketing claims the data cannot carry. Mechanism is a reason to run a trial. It is not a substitute for one.

Why intranasal delivery makes semax hard to evaluate

Peptides are poorly suited to oral delivery: they are hydrolyzed in the gut and cross the blood-brain barrier badly. Intranasal administration is used to bypass both problems, with transport thought to occur partly along olfactory and trigeminal pathways.

The rat data give a sense of scale. Intranasal delivery put a substantially higher fraction of the administered dose into brain tissue than intravenous — but in both cases the fraction reaching the brain was a fraction of one percent.

There are no published pharmacokinetic studies of semax in humans by any route. FDA searched and found none. Every “semax has a half-life of a few minutes” claim you will encounter is extrapolated from rat blood and brain tissue, where the peptide is rapidly hydrolyzed to the tripeptide Pro-Gly-Pro. That extrapolation may well be right. It has not been measured in a person.

Absorption from a nasal spray depends on congestion, allergic rhinitis, mucosal condition, spray technique, head position, formulation pH and viscosity, and device consistency. FDA’s quality assessment noted that for a metered-dose nasal spray, pump delivery, spray content uniformity, spray pattern and droplet size distribution are critical quality attributes — and that no information about the container, closure or pump was available in the nominations or the published literature.

What that means for you: two people using the same product can receive meaningfully different exposure, and so can the same person on different days. If you are trying to detect a real effect, inconsistent absorption will make a genuine one look unreliable and an imaginary one look convincing.

Semax side effects, interactions, and who should avoid it

Reported adverse effects. In the human studies FDA reviewed, adverse events were either not discussed or reported as absent. That absence reflects poor reporting, not established safety.

FDA’s search of the FAERS adverse event database through December 2025 retrieved exactly one report. A consumer reported that in May 2024 she experienced ocular pain and eye burning after using semax 0.1% nasal drops purchased online. She reported hospitalization following the exposure, and that the eye pain had not resolved as of the time of the report a year later. Two literature searches of PubMed identified no published case reports of adverse events in humans.

One report is not a safety signal. It is also not reassurance — compounders are generally not required to report adverse events to FDA, and a substance sold as a research chemical has no surveillance system behind it at all.

User-reported effects commonly include nasal irritation and dryness, headache, fatigue, nausea, restlessness, irritability and disrupted sleep. Persistent nasal irritation is a reason to stop, not an inconvenience to absorb.

What has never been done. FDA identified no acute toxicity studies, no repeat-dose toxicity studies, no developmental or reproductive toxicity studies, and no adequately designed carcinogenicity study. There are no clinical immunogenicity or aggregation data — a specific concern for peptides, which can aggregate and provoke immune responses, particularly by injected and nasal routes. No study of semax’s abuse potential exists either.

Two interaction signals almost nobody mentions

Bleeding risk. Multiple rodent studies report anticoagulant and antithrombotic activity, including increased fibrinolytic activity and reduced platelet aggregation. Notably, semax was inactive in vitro in the same work — the effect may be driven by the Pro-Gly-Pro metabolite. FDA cited this as raising concern about bleeding risk, particularly in people already at risk or taking medications that increase it. Relevant drug classes: anticoagulants, antiplatelet agents, NSAIDs, and SSRIs, all of which affect hemostasis. No dose-response relationship has been established, so there is no basis for assuming a “safe” amount.

Stimulant potentiation. In mice, semax potentiated amphetamine-induced dopamine release in the striatum and amphetamine-induced locomotor activity. FDA called this concerning, because increased striatal dopaminergic tone is the response characteristic of drugs of abuse, and noted that no study of semax’s abuse potential exists. Relevant drug classes: prescription stimulants, including those used for ADHD.

Evidence tier: Mechanistic for both. Neither has been demonstrated in humans. Both concern outcomes serious enough that a rodent signal is decision-relevant.

Who should avoid semax

A clinician’s input is necessary for anyone who:

is pregnant, planning pregnancy, or breastfeeding — no reproductive toxicity data exist
has a neurological or psychiatric condition, including a history of mania, psychosis, or severe anxiety
has a seizure history
has cardiovascular disease, unstable blood pressure, or any bleeding disorder
takes anticoagulants, antiplatelet agents, SSRIs, stimulants, or any psychiatric or neurological medication
is under 18

Stop use and seek medical attention promptly for severe headache, difficulty breathing, facial or throat swelling, chest symptoms, unusual bruising or bleeding, marked mood change, or any new neurological or visual symptom.

If low mood, panic, persistent concentration problems or exhaustion are affecting your daily function, an assessment by a clinician is both more useful and considerably faster than working through unapproved peptides. Semax is not an approved treatment for depression, anxiety, ADHD, stroke or cognitive decline anywhere in the US or EU, and it should not be used in place of care. If the problem is persistent mental fog, our piece on what causes brain fog and what the evidence supports starts from the causes rather than the compounds.

Semax and anti-doping: an unresolved category, not a green light

Semax is not named on the WADA Prohibited List. That is not clearance.

Category S0 covers any pharmacological substance not addressed elsewhere on the List and with no current approval by any governmental regulatory health authority for human therapeutic use. Semax sits awkwardly against that wording: Russia’s health authority has approved it, which arguably takes it outside S0’s literal terms, while every other regulator has not.

The practical position: the category question is genuinely unresolved, anti-doping operates on strict liability, and sanctions can be imposed non-analytically — on the basis of admissions, possession or records, with no positive test. An athlete should obtain a written ruling from their national anti-doping organization before use, not afterward. “It wasn’t on the list” has never been a successful defense.

If you are going to proceed anyway: an honest risk assessment

This is not a buying guide, and we do not sell semax. What follows is risk assessment for readers who have already decided.

The identity problem is documented, not hypothetical. Semax free base (C₃₇H₅₁N₉O₁₀S, 813.93 g/mol, CAS 80714-61-0) and semax acetate (C₃₉H₅₅N₉O₁₂S, 874.0 g/mol) are different active pharmaceutical ingredients. FDA noted that “semax” is a common name rather than a United States Adopted Name, that it has encountered multiple salts and derivatives sold commercially under the same common name, and that inconsistent naming is itself a patient safety risk — a person may be dosed with a different substance than the one ordered.

When FDA examined the certificates of analysis submitted with the two nominations, it found exactly that failure: the CoA refers to one substance by name in the title and a different substance by CAS number and molecular formula. Both submitted CoAs were headed “Semax Acetate” while carrying the free base’s CAS number, molecular formula and molecular weight. These were documents submitted to a federal regulator in support of a formal nomination.

A practical check anyone can run in two minutes. Open the certificate of analysis. Confirm that the title, the CAS number, the molecular formula and the molecular weight all describe the same substance. If the document says “acetate” in the header and carries 813.93 as the molecular weight, the seller either does not know what they are selling or is not checking.

Beyond identity, the gaps FDA could not close on any available material were: impurity limits and testing results, aggregation data, microbial bioburden, and bacterial endotoxin testing. One submitted CoA disclosed a total impurity limit of up to 1.0% and another up to 2.0% — with no information anywhere about what those impurities actually are. For nasal spray specifically, no information existed about the device — container, closure or pump — which determines what dose reaches the mucosa.

A degraded, misidentified or inconsistently delivered product creates two problems at once: a safety risk, and a worthless experiment. A null result from bad material tells you nothing about semax.

Any seller claiming a peptide reliably makes people smarter, “erases brain fog” or substitutes for medical care is telling you about themselves, whatever they are telling you about the product.

Myth vs. reality

Common claim	More accurate picture
“Semax is a proven nootropic”	No published English-language controlled trial has tested cognitive performance in healthy adults. The one placebo-controlled healthy-adult study measured fMRI network topography
“It’s an ACTH fragment, so it raises cortisol”	Pro-Gly-Pro replaces the residues that carry corticotropic and melanotropic activity. It does not stimulate adrenal steroidogenesis
“Its half-life is about four minutes”	There are no human pharmacokinetic studies of semax by any route. That figure comes from rats
“Russian approval proves it works”	Russian approval reflects one regulator’s standards. The supporting literature is Russian-language, excluded from FDA’s review on procedural grounds, and independently unreplicated
“It helps migraine”	The single study in migraine and trigeminal neuralgia was uncontrolled and unblinded. It found no change on any measure in typical trigeminal neuralgia, and its authors concluded semax has no analgesic activity by itself
“N-Acetyl Semax Amidate is objectively stronger”	The modifications are chemically plausible. The potency ratios are community estimates. No head-to-head trial exists, and FDA’s 2026 review covered only semax free base and semax acetate
“The FDA panel approved it”	The panel recommended it for a compounding list, against FDA staff’s recommendation, after both nominations had been withdrawn. Compounding remains unlawful and the substance remains unapproved

If you test it, run a test that can actually answer the question

The most useful question is not “does semax work” but “what problem am I solving, and what else is shaping it.” Someone with adequate sleep, a defined task list and controlled caffeine intake will get a different result from someone on four hours’ sleep switching contexts every two minutes. In the second case, no peptide is the limiting variable — and if stimulant load is the issue, caffeine-free approaches to steady energy address it more directly.

A test worth running looks like this:

Pick one narrow, measurable target. Completion time on a repeatable work block, error rate on a familiar task, or delayed recall after a study session.
Establish a baseline first. A week of measurement before you start is what makes the “after” interpretable.
Change one variable. Adding semax to four other compounds guarantees an uninterpretable outcome.
Set the stop point in advance. Decide the date and the threshold that counts as failure before expectation has a chance to rewrite your memory.
Log adverse effects with the same discipline as benefits. Selective attention runs in both directions.
Don’t start during chaos. New job, deadline crunch, disrupted sleep — the noise will swamp any signal.

The most common failure is not a bad protocol. It is treating mechanism as evidence.

The bottom line

Semax is a chemically interesting molecule with a real clinical history in one country, a mechanistic literature genuinely worth reading, and a human evidence base for cognitive enhancement that is close to empty. FDA’s 2026 evaluation is the most thorough English-language assessment that exists, and it concluded the effectiveness evidence was insufficient and the safety information inadequate. An advisory committee then voted the other way without any new data, on substances whose nominations had already been withdrawn. Both of those things are true.

This is not for you if you are pregnant or breastfeeding, under 18, taking anticoagulants, antiplatelet drugs, SSRIs or stimulants, managing a psychiatric or seizure condition, competing under anti-doping rules, or hoping a nasal spray will substitute for sleep, treatment or a workload you cannot sustain. It is also not for you if you want certainty — there is none available here.

The best possible outcome is not a dramatic feeling. It is a repeatable improvement in useful work, achieved without sacrificing sleep, mood stability or judgment. Most of the time, that improvement comes from somewhere other than a bottle.

Frequently asked questions

Is semax legal in the US and EU? Semax is not approved by the FDA or the EMA and is not a lawful dietary supplement ingredient in either jurisdiction. It is sold as a research chemical. In July 2026 an FDA advisory committee recommended adding semax to the 503A compounding list, but compounding remains unlawful until FDA accepts that recommendation and completes rulemaking.

How long does semax take to work? Users typically describe onset within tens of minutes, and the one placebo-controlled healthy-adult imaging study detected brain network differences at 5 and 20 minutes after a single intranasal dose. Given how variable intranasal absorption is and how strong expectancy effects are, early impressions are the least reliable data you will gather about your own response.

Is semax a stimulant? No. Semax is not classed as a stimulant and does not produce stimulant-like arousal. Some users report restlessness or disrupted sleep regardless. More relevant: in mice, semax potentiated amphetamine-induced dopamine release in the striatum, which is a reason to be cautious about combining it with prescription stimulants.

What’s the difference between semax and N-Acetyl Semax Amidate? N-Acetyl Semax Amidate caps both ends of the molecule to resist enzymatic degradation. The chemistry is sound. The claim that it is several times more potent comes from community comparison, not from any head-to-head trial. The published clinical literature uses base semax.

Can semax replace treatment for ADHD, depression, or anxiety? No. Semax is not an approved treatment for any of these conditions in the US or EU. FDA specifically declined to evaluate it for ADHD because it could not find supporting literature. Using an unapproved peptide in place of assessment and evidence-based care carries real cost, and the delay is usually the most expensive part.

Does semax interact with any medications? Rodent studies show anticoagulant and antiplatelet activity, which FDA flagged as a bleeding concern. That makes anticoagulants, antiplatelet agents, NSAIDs and SSRIs the classes to raise with a clinician. Semax also potentiated amphetamine effects in mice, making prescription stimulants a second class of concern. None of this has been tested in humans.

References

U.S. Food and Drug Administration. FDA Briefing Document — Pharmacy Compounding Advisory Committee Meeting, July 23–24, 2026. fda.gov/media/193342/download
U.S. Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee — meeting page, including the FDA Evaluation for Semax-related bulk drug substances. fda.gov
U.S. Food and Drug Administration. FDA Evaluation of Semax-Related Bulk Drug Substances (Semax (free base) and Semax acetate), memorandum dated 11 May 2026, prepared for the Pharmacy Compounding Advisory Committee. Nomination dockets FDA-2015-N-3534-0284 (Wells Pharmacy Network) and FDA-2018-N-2973-0002 (LDT Health Solutions); both withdrawn.
Lebedeva IS, Panikratova YaR, Sokolov OYu, Rumshiskaya AD, Kost NV, Myasoedov NF, Kupriyanov DA. Effects of Semax on the default mode network of the brain. Bull Exp Biol Med. 2018;165(5):653–656. doi:10.1007/s10517-018-4234-3. PMID 30225715
Panikratova YaR, Lebedeva IS, Sokolov OYu, Rumshiskaya AD, Kupriyanov DA, Kost NV, Myasoedov NF. Functional connectomic approach to studying Selank and Semax effects. Dokl Biol Sci. 2020;490(1):9–11. doi:10.1134/S001249662001007X. PMID 32342318
Koroleva MV, Meizerov EE, Nezavibat’ko VN, Kamenskii AA, Dubynin VA, Yakovlev YuB. Analgesic action of the new drug Semax. Bull Exp Biol Med. 1996;122(11):1107–1109. doi:10.1007/BF02447659. PMID 8998343
World Anti-Doping Agency. Prohibited List — category S0, substances with no current regulatory approval for human therapeutic use.

Russian-language clinical literature on Semax in cerebrovascular indications was excluded from FDA’s review under 21 CFR 10.20(c)(2), which requires verified English translations. That exclusion is procedural and is not an assessment of study quality.

This article is for information and education only. It is not medical advice, and nothing here is a recommendation to use semax. Semax is not approved by the FDA, EMA or MHRA, and is not authorized as a dietary supplement in the US or EU. Discuss any decision about an unapproved compound, and any interaction with medication you take, with a qualified healthcare professional who knows your history.

Semax: What the Human Evidence Actually Shows